{"disease":{"id":"nad","name":"nad"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active ankylosing spondylitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"lonapegsomatropin","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skytrofa","generic_name":"LONAPEGSOMATROPIN","company_name":"Ascendis Pharma Encocrinology Div A/S","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":"446","mechanism":"Skytrofa works by mimicking the natural growth hormone to stimulate growth in individuals with growth hormone deficiency."},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"estradiol-valerate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"norethisterone","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"colecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"undecanoate","indication_name":"Primary hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"undecanoate","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"norethynodrel","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noretynodrel","generic_name":"NORETHYNODREL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"norethynodrel","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"cholecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"testosterone","indication_name":"Chemotherapy-Induced Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"depo-testosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"estrone-sulphate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ogen .625","generic_name":"estrone sulphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Steryl-sulfatase","drug_class":"estropipate","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"menest","indication_name":"Female hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"synarel","indication_name":"Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"aldactone","indication_name":"Edema in nephrotic syndrome with inadequate response to other treatments","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options would be otherwise inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"calciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"testosteron","indication_name":"Chemotherapy-Induced Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"alendronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"oxymesterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"oxymesterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"oxymesterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"estring","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"fluoxymesterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluoxymesterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluoxymesterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alendronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"testosterone-cypionate-200mg-3ml","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosterone cypionate (200mg/3ml)","company_name":"Leticia Maria Defendi Barboza Marson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgenic steroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tranexamic-acid","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"TRANEXAMIC ACID","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"Antifibrinolytic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis."},{"drug_id":"estradiol-cypionate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"corifollitropin-alfa","indication_name":"Adolescent males with hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Org 36286","generic_name":"CORIFOLLITROPIN ALFA","company_name":"Merck Sharp & Dohme Limited","drug_phase":"marketed","molecular_target":"Follicle-stimulating hormone receptor","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotrophin","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choriogonadotropin","generic_name":"chorionic gonadotrophin","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"gonadorelin","indication_name":"Diagnostic Test for Gonadotropin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fertagyl","generic_name":"GONADORELIN","company_name":"","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"gonadorelin","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"zoledronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"mestranol","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norinyl 1+50 28-Day","generic_name":"MESTRANOL","company_name":"","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone-undecanoate","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aveed","generic_name":"TESTOSTERONE UNDECANOATE","company_name":"Marius","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":70,"revenue":null,"mechanism":"Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone."},{"drug_id":"testosterone-undecanoate","indication_name":"Primary hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aveed","generic_name":"TESTOSTERONE UNDECANOATE","company_name":"Marius","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":70,"revenue":null,"mechanism":"Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone."},{"drug_id":"elonva","indication_name":"Adolescent males with hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elonva","company_name":"University Medical Centre Ljubljana","drug_phase":"marketed","molecular_target":"Follicle-stimulating hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amchafibrin","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amchafibrin","company_name":"Fundación Pública Andaluza Progreso y Salud","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"transamin","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"transamin","company_name":"Erzincan Military Hospital","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"somatrogon","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"zoledronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"depo-testosterone","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"depo-testosterone","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"undecanoate","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"undecanoate","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"somapacitan-beco","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"chembl-chembl4297830","indication_name":"Growth failure due to inadequate growth hormone secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOMATROGON","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"tezepelumab","indication_name":"Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"testosterone-enantate","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyosted (Autoinjector)","generic_name":"testosterone enantate","company_name":"Endo","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":80,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06583408","title":"The REgistry of Very Early Estrogen and AnovuLation","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03177421","title":"Health Information Technology to Improve Bedtime Media Use in Children","phase":"NA","overall_status":"TERMINATED","enrollment_count":60100,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT03484260","title":"Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone","phase":"","overall_status":"COMPLETED","enrollment_count":27778,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT00341458","title":"Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03748420","title":"Medication Adherence Clinical Decision Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":5421,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT03518034","title":"A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":5246,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03067181","title":"Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1780,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00001275","title":"Ovarian Follicle Function in Patients With Primary Ovarian Failure","phase":"","overall_status":"COMPLETED","enrollment_count":1134,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT07085455","title":"The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN)","phase":"NA","overall_status":"RECRUITING","enrollment_count":946,"lead_sponsor_name":"Dong Zhang","has_results":false},{"nct_id":"NCT02471404","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":939,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04478240","title":"Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School","phase":"NA","overall_status":"COMPLETED","enrollment_count":924,"lead_sponsor_name":"Oregon Research Behavioral Intervention Strategies, Inc.","has_results":false},{"nct_id":"NCT02681094","title":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":905,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01500447","title":"Inherited Reproductive Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT07476222","title":"PREDICTORS OF TESTOSTERONE DECLINE IN MIDDLE-AGED MEN","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Andijan State Medical Institute","has_results":false},{"nct_id":"NCT03455647","title":"Enhancing Milk Consumption for Improved Nutrition in Rwanda","phase":"NA","overall_status":"COMPLETED","enrollment_count":746,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04369222","title":"The Copenhagen Analgesic Study","phase":"","overall_status":"COMPLETED","enrollment_count":685,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT07316387","title":"Neurobehavioral Development in Toddlers and Preschoolers in Relation to Prenatal Exposure of Mild Analgesics (NeuroToP - a COPANA Follow up)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":685,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04456296","title":"A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Endo Pharmaceuticals","has_results":true},{"nct_id":"NCT05110391","title":"Sperm Retrieval Rates in Non-obstructive Azoospermic Men Subjected to Gonadotropin Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"ANDROFERT - Clinica de Andrologia e Reproducao Humana","has_results":false},{"nct_id":"NCT03437109","title":"Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":554,"lead_sponsor_name":"Besins Healthcare","has_results":false},{"nct_id":"NCT06614049","title":"AdLip: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medication","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"National University of Singapore","has_results":false},{"nct_id":"NCT03709277","title":"Interventions to Improve Specialty Medication Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT02375204","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":420,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06427941","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT03747003","title":"Gonadal Function in Young to Middle Aged HIV-infected Men","phase":"","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Modena","has_results":false},{"nct_id":"NCT03198728","title":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Marius Pharmaceuticals","has_results":true},{"nct_id":"NCT00053352","title":"Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06280807","title":"Observation of Environment and Reproductive-Endocrine Effects","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT07085832","title":"Assessment of Cardiopumonary Resuscitation (CPR) Competency Post ALS Course","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Hepatology & Tropical Medicine Research Institute","has_results":false},{"nct_id":"NCT07348757","title":"rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Centrum Clinic IVF Center","has_results":false},{"nct_id":"NCT02585713","title":"Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT03388099","title":"Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Instituto Valenciano de Infertilidad, IVI VALENCIA","has_results":false},{"nct_id":"NCT02730169","title":"Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"Mereo BioPharma","has_results":true},{"nct_id":"NCT00104676","title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"UNICANCER","has_results":true},{"nct_id":"NCT03436784","title":"The Indiana SNAP-Ed Long-term Study Sequel","phase":"NA","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Purdue University","has_results":false},{"nct_id":"NCT00914823","title":"Kisspeptin Administration in the Adult","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03164902","title":"Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence","phase":"NA","overall_status":"UNKNOWN","enrollment_count":253,"lead_sponsor_name":"Proteus Digital Health, Inc.","has_results":false},{"nct_id":"NCT05167578","title":"Identifying Reasons for Non-adherence in Patients With Multi-morbidity","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT04274894","title":"A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03254641","title":"Calciotropic Effects After HCG Stimulation Test","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Martin Blomberg Jensen","has_results":false},{"nct_id":"NCT04049331","title":"Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Seattle Institute for Biomedical and Clinical Research","has_results":false},{"nct_id":"NCT02758431","title":"Cardiovascular Outcomes of Low Testosterone","phase":"NA","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04301765","title":"Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Seattle Institute for Biomedical and Clinical Research","has_results":false},{"nct_id":"NCT03281187","title":"Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":228,"lead_sponsor_name":"FBM Industria Brasileira Ltda","has_results":false},{"nct_id":"NCT04733274","title":"Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":227,"lead_sponsor_name":"Boston College","has_results":false},{"nct_id":"NCT07266935","title":"Posterior Pericardiotomy for Prevention of POAF After Cardiac Surgery: RCT in Yemen","phase":"NA","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Taiz University - Faculty of Medicine","has_results":false},{"nct_id":"NCT03687606","title":"Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05420766","title":"Impact of Sleep Duration on Immune Balance in Urban Children With Asthma","phase":"NA","overall_status":"RECRUITING","enrollment_count":204,"lead_sponsor_name":"Rhode Island Hospital","has_results":false},{"nct_id":"NCT03317028","title":"CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Center Laboratories, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}